Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011551 | 1.00 | ALDH1A1 (0.38) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL14081718 | 0.89 | PRMT5 (0.45) | PRMT5WDR77 | |
| SCHEMBL4016824 | 0.89 | PRMT5 (0.45) | PRMT5WDR77 | |
| SCHEMBL1737262 | 0.87 | XDH (0.39) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13650024 | 0.84 | ALDH1A1 (0.36) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL4020271 | 0.80 | ALDH1A1 (0.35) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL13598728 | 0.80 | ALDH1A1 (0.35) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL30004448 | 0.78 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL21683024 | 0.78 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL21683022 | 0.78 | PRMT5 (0.41) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629328-B2 | Nucleoside derivatives for treating hepatitis C virus infection | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7432248-B2 | Nucleoside derivatives for treating Hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NSUN2 | ALDH1A1 344/4885LMNA 1332/4885TP53 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.